CSF1R and glioblastoma: Given these encouraging findings in preclinical models and the fact that no clinical benefits were achieved with PLX3397 treatment in GBM patients (21), the results of clinical trials testing novel therapeutic strategies with CSF-1R inhibition combined with IGF-1R/PI3K pathway inhibition, radiotherapy, or immunotherapy are highly anticipated.